Celldex Therapeutics Inc. (CLDX)

0.4207 -0.0042 (-0.988%)

IEX Real-Time Price

August 17, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 0.4249

Price Open 0.4266

Volume: 710,245

Avg Volume: 1.33M

Market Cap: 68.34M

P/E Ratio -0.69

52 Wk Range 0.4105-3.26



CLDX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
155.83M
3.53M
2.35
2.27%

2018-07-13
136.78M
3.83M
1.10
2.80%

2018-06-29
136.78M
5.35M
1.29
3.91%

2018-06-15
136.77M
8.65M
2.68
6.32%




CLDX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-08
Q2 2018
AMC
-0.14 (3)
0.00
0.00

2018-05-10
Q1 2018
N/A
-0.17 (3)
-0.19
-0.02

2018-05-08
Q1 2018
N/A
-0.17 (3)
0.00
0.00

2018-03-13
Q4 2017
N/A
-0.23 (4)
-0.17
0.06

News

Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q2 2018 Results - Earnings Call Transcript (2018-08-08 22:17 SeekingAlpha)

Celldex Therapeutics, Inc. (CLDX) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET Executives Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Founder, President, Chief Executive Officer and Director Tibor Keler - Founder, …

 


Statistics

Shares Outstanding: 162.44M

Top 15 Institution Percent: 48.50

Price To Sales: 4.86

Price To Book: 0.53

Revenue: 3.92M

Gross Profit: N/A

Cash: 140.53M

Debt: N/A

Return On Assets: -62.82

Return On Equity: -91.65

Profit Margin: N/A

Price History

Beta: 2.50

50-day Moving Avg: 0.51

200-day Moving Avg: 1.74

YTD Change: -85.59

5-day Change: 1.08

1-month Change: -18.91

3-month Change: -39.29

6-month Change: -82.25

1-year Change: -82.17

Revenue Per Share: 0.00

Revenue Per Employee: 19919.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Celldex Therapeutics Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.